z-logo
open-access-imgOpen Access
Rapid Profiling of Tumor‐Immune Interaction Using Acoustically Assembled Patient‐Derived Cell Clusters
Author(s) -
Ao Zheng,
Wu Zhuhao,
Cai Hongwei,
Hu Liya,
Li Xiang,
Kaurich Connor,
Chang Jackson,
Gu Mingxia,
Cheng Liang,
Lu Xin,
Guo Feng
Publication year - 2022
Publication title -
advanced science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.388
H-Index - 100
ISSN - 2198-3844
DOI - 10.1002/advs.202201478
Subject(s) - tumor microenvironment , cancer research , immune system , cancer immunotherapy , immunotherapy , melanoma , medicine , biology , immunology
Tumor microenvironment crosstalk, in particular interactions between cancer cells, T cells, and myeloid‐derived suppressor cells (MDSCs), mediates tumor initiation, progression, and response to treatment. However, current patient‐derived models such as tumor organoids and 2D cultures lack some essential niche cell types (e.g., MDSCs) and fail to model complex tumor‐immune interactions. Here, the authors present the novel acoustically assembled patient‐derived cell clusters (APCCs) that can preserve original tumor/immune cell compositions, model their interactions in 3D microenvironments, and test the treatment responses of primary tumors in a rapid, scalable, and user‐friendly manner. By incorporating a large array of 3D acoustic trappings within the extracellular matrix, hundreds of APCCs can be assembled within a petri dish within 2 min. Moreover, the APCCs can preserve sensitive and short‐lived (≈1 to 2‐day lifespan in vivo) tumor‐induced MDSCs and model their dynamic suppression of T cell tumor toxicity for up to 24 h. Finally, using the APCCs, the authors succesully model the combinational therapeutic effect of a multi‐kinase inhibitor targeting MDSCs (cabozantinib) and an anti‐PD‐1 immune checkpoint inhibitor (pembrolizumab). The novel APCCs may hold promising potential in predicting treatment response for personalized cancer adjuvant therapy as well as screening novel cancer immunotherapy and combinational therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here